Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

Journal of Clinical Investigation

Volumn 121, Issue 12, 2011, Pages 4700-4711

  Chakravarty, Debyani ^a   Santos, Elmer ^a   Ryder, Mabel ^a   Knauf, Jeffrey A ^a   Liao, Xiao Hui ^b   West, Brian L ^c   Bollag, Gideon ^c   Kolesnick, Richard ^a   Thin, Tin Htwe ^a   Rosen, Neal ^a   Zanzonico, Pat ^a   Larson, Steven M ^a   Refetoff, Samuel ^b   Ghossein, Ronald ^a   Fagin, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLX 4720; RADIOACTIVE IODINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN CELL; HYPOTHYROIDISM; MOUSE; NONHUMAN; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; THYROID FOLLICLE CELL; THYROID PAPILLARY CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CARCINOMA, PAPILLARY; DIPHENYLAMINE; DNA DAMAGE; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENES, SYNTHETIC; HUMANS; INDOLES; IODINE RADIOISOTOPES; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; NEOPLASM PROTEINS; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID GLAND; THYROID NEOPLASMS;

EID: 84055191090     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46382     Document Type: Article

References (46)

1. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
2. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-1457. (Pubitemid 36373628)
3. Nikiforova MN, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399-5404. (Pubitemid 37452745)
4. Xing M, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373-6379. (Pubitemid 41759286)
5. Elisei R, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93(10):3943-3949.
6. Ricarte-Filho JC, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885- 4893.
7. Sedliarou I, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004;25(6):1729-1735.
8. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science. 2002;297(5578):63-64. (Pubitemid 34743088)
9. Yokoyama K, Imamoto F. Transcriptional control of the endogenous MYC protooncogene by antisense RNA. Proc Natl Acad Sci U S A. 1987;84(21):7363-7367. (Pubitemid 18035706)
10. Loke SL, Stein C, Zhang X, Avigan M, Cohen J, Neckers LM. Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr Top Microbiol Immunol. 1988;141:282-289.
11. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991;51(6):1744-1748.
12. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog. 1997;20(2):251-258. (Pubitemid 27508889)
13. Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer. 1994;70(5):819-825. (Pubitemid 24331071)
14. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005;65(6):2465-2473. (Pubitemid 40490159)
15. Mesa C Jr, et al. Conditional activation of RET/ PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 2006;66(13):6521-6529.
16. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4(2):199-207. (Pubitemid 29456888)
17. Chin L, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999; 400(6743):468-472. (Pubitemid 29361802)
18. Fisher GH, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15(24):3249-3262. (Pubitemid 34008191)
19. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24(1):57-60. (Pubitemid 30041421)
20. Moody SE, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2(6):451-461. (Pubitemid 41043950)
21. Dhomen N, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15(4):294-303.
22. Ball DW, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab. 2007;92(12):4712-4718. (Pubitemid 350223448)
23. Leboeuf R, et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93(6):2194-2201. (Pubitemid 351831535)
24. Salerno P, et al. Cytostatic activity of adenosine triphosphate- competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010;95(1):450-455.
25. Nucera C, et al. B-Raf(V600E) and thrombospondin- 1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010;107(23):10649-10654.
26. Solit DB, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-362. (Pubitemid 43128863)
27. Joseph EW, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010;107(33):14903-14908.
28. Tsai J, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041-3046. (Pubitemid 351723664)
29. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-819.
30. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
31. D'Cruz CM, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001; 7(2):235-239. (Pubitemid 32148492)
32. Franco AT, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A. 2011; 108(4):1615-1620.
33. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res. 2011;71(11):3863-3871.
34. Jechlinger M, Podsypanina K, Varmus H. Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev. 2009;23(14):1677-1688.
35. Soares P, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22(29):4578-4580. (Pubitemid 36920701)
36. Frattini M, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23(44):7436-7440. (Pubitemid 39382146)
37. De Vita G, et al. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ. 1998; 9(1):97-103.
38. Portella G, et al. Human N-ras, TRK-T1, and RET/ PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res. 1999;11(9):421-427.
39. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RASMAP kinase. Oncogene. 2003;22(28):4406-4412. (Pubitemid 36897971)
40. Riesco-Eizaguirre G, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009;69(21):8317-8325.
41. Costamagna E, Garcia B, Santisteban P. The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factor-beta repression of the sodium/iodide symporter gene. J Biol Chem. 2004; 279(5):3439-3446. (Pubitemid 38140582)
42. Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
43. Durante C, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007; 92(7):2840-2843. (Pubitemid 47037399)
44. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques. 2002; 32(6):1372-1374.
45. Pohlenz J, Maqueem A, Cua K, Weiss RE, Van Sande J, Refetoff S. Improved radioimmunoassay for measurement of mouse thyrotropin in serum: strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid. 1999;9(12):1265-1271. (Pubitemid 30038940)
46. Sheh Y, Koziorowski J, Balatoni J, Lom C, Dahl JR, Finn RD. Low energy cyclotron production and chemical separation of "no carrier added" iodine- 124 from a reusable, enriched tellurium-124 dioxide/ aluminum oxide solid solution target? Radiochimica Acta. 2000;88(3-4):169-173.